Selective estrogen receptor degraders (SERDs) are a type of hormone therapy used to treat estrogen receptor-positive (ER+) MBC. Oral SERDs are taken by mouth. SERDs attach to and break down the estrogen receptor, which stops or slows cancer cells from growing. Currently, fulvestrant (Faslodex®) is the only SERD approved by the FDA for MBC and can only be given by injection. However, many clinical trials are studying new SERDs, including giredestrant, amcenestrant, and others, that can be given orally.
Visit the links below to learn about EMERALD phase III trial results for an oral SERD called elacestrant, as well as other oral SERDs in development.
- Breastcancer.org: Experimental Elacestrant Shows Promise for Pre-Treated Metastatic, Hormone Receptor-Positive, HER2-Negative Breast Cancer
- Healio (Video): Positive Trial Results on Elacestrant
- Healio: Elacestrant Extends Progression-Free Survival Among Certain Women with MBC
Other Oral SERDs in Clinical Trials
- OncLive: SERDs Represent the Next Generation of ER-Targeting Therapy in Breast Cancer
- Pharmaphorum: Oral SERD Giredestrant in Advanced Breast Cancer
- OncLive: Amcenestrant Misses PFS End Point in ER+/HER2– Advanced or Metastatic Breast Cancer
Clinical Trials That Include SERDs
- Metastatic Trial Search: MBC Trials That Include SERDs
- Solid Tumor Trials: Trials That May Include SERDs
Last Modified on December 22, 2022
Tags:Hormone Receptor PositiveAreas of ResearchResearch News